Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dr Mark Parry-Billings named CEO of Topigen

This article was originally published in Scrip

Executive Summary

Topigen Pharmaceuticals, a clinical-stage biopharmaceutical company specialising in developing products for respiratory disorders, has named Dr Mark Parry-Billings chief executive officer. Dr Parry-Billings joined the company in 2007 as chief development officer and expanded his role to lead the company's operations in early 2008.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts